GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as m ...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=88044&from=3 CLASS PERIOD: December 1, 2023 t ...

While their share prices have traveled different paths recently, the similarity between the two companies is striking.Altimmune (ALT 4.15%) and Viking Therapeutics (VKTX 4.41%) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's shares are up by 610% over the last three years, Altimmune's are down by 54%.However, there's more than one argument for why Altimmune's next act could look a lot more like Viking's trajectory. So let's ...

NEW YORK, June 29, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 5, 2024.To join the Altimmune class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq. toll ...

The market for weight loss medicines keeps getting hotter and hotter.For most of its existence, Altimmune (ALT 4.15%) has been a little-known biotech aspiring to compete in a world dominated by whales like Novo Nordisk (NVO -1.21%), the maker of the hit weight loss drug Wegovy and the blockbuster Ozempic for type 2 diabetes.But if management's three-word hunch about the company's lead program is right -- and there's at least one critical piece of evidence hinting that it is -- Wegovy's reign could face a se ...

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), of the important July 5, 2024 lead plaintiff deadline. SO WHAT: If you purchased Altimmune securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT T ...

NEW YORK, June 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/altimmune-inc-loss-submission-form/?id=87822&from=4CLASS PERIOD: December 1, 2023 to April ...

pidjoe/E+ via Getty Images The small biotech sector has underperformed the major indices in a major way so far in 2024. While the NASDAQ (COMP.IND) and S&P 500 (SP500) are both up in the mid-teens so far this year, the SPDR® S&P Biotech ETF (XBI) up just over three percent in 2024. It should be noted that AI juggernaut Nvidia Corporation (NVDA) has accounted for approximately a third of the gains in the major indices year to date. Seeking Alpha The small biotech arena should perform better as the Feder ...

ATLANTA, June 26, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company’s business, operations, and prospects, including allegations that: (i) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug’s eff ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. due to allegations of misleading statements regarding the efficacy and market potential of its drug pemvidutide, with a deadline for investors to seek lead plaintiff status in a federal securities class action by July 5, 2024 [1][3]. Group 1: Allegations Against Altimmune - The complaint alleges that Altimmune and its executives violated federal securities laws by making false and misleading statements about pemvidutide's competitive prospects and overstating the company's potential for finding a strategic partner [3]. - A report by Kerrisdale Capital criticized pemvidutide's chances of competing against existing GLP-1 agonists, stating that even a 15.6% weight loss is insufficient compared to competitors like semaglutide and tirzepatide, which also control blood sugar [4]. - Following the Kerrisdale Report, Altimmune's stock price dropped by $1.94, or 18.65%, closing at $8.46 per share on February 13, 2024 [4]. Group 2: Market Reactions and Analyst Opinions - On April 29, 2024, Guggenheim Securities downgraded Altimmune's stock from buy to neutral, citing an increasingly unlikely partnership for pemvidutide and highlighting the lack of a major partnership or M&A event as a significant concern [5]. - This downgrade led to a further decline in Altimmune's stock price by $0.87, or 11.98%, closing at $6.39 per share [5]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $75,000 between December 1, 2023, and April 26, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class who has the largest financial interest and is typical of class members [6].